Kura Oncology 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Kura Oncology reported 3rd quarter ComZifty net product revenue of $13.9 million, up 53% sequentially, with approximately 150 new patient starts, up approximately 30%, and more than 420 total prescriptions, up 65%.
- The company maintained a majority share of menin inhibitor new patient starts in relapsed/refractory NPM1-mutated AML, and 170 accounts had prescribed ComZifty, up 40% quarter over quarter.
- ComZifty had coverage for nearly 100% of covered lives, and nearly half of patients in the available claims dataset received it in combination with other approved agents, primarily venetoclax and azacitidine or FLT3 inhibitors.
- Collaboration revenue from the Kowa Kirin partnership was $8.9 million, compared with $20.8 million in the prior year's quarter; research and development expenses decreased 2% to $67 million, selling, general, and administrative expenses decreased 8% to $30.2 million, and net loss decreased 5% to $70.2 million.
- Share-based compensation expense included in net loss decreased 25% to $8.2 million, and Kura ended September with $492 million in cash, cash equivalents, and short-term investments.
- Kura raised approximately $32 million through its At-the-Market Equity Program during the quarter and renewed the program with $150 million of capacity; its Oberlin Capital agreement provides up to $300 million in potential funding, including $50 million in debt funding and a $5 million equity investment received at closing.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, everyone. My name is Ronnie, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology third quarter 2026 financial results earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, and if you have joined via the webinar, please use the raised hand icon, which can be found on the bottom of your webinar application. To allow everyone the opportunity to participate, we ask that you please limit yourself to one question and one follow-up question. If time permits at the end of the Q&A session, we invite you to rejoin the queue for additional questions.
At this time, I would like to turn the call over to Greg Mann, SVP of Investor Relations and Corporate Affairs of Kura Oncology. Please go ahead. Thank you, Ronnie.
Good afternoon, everyone. Joining me today are Dr. Troy Wilson, President and Chief Executive Officer, Brian Powl, Chief Commercial Officer, Dr. Mollie Leoni, Chief Medical Officer, and Jennifer Fulk, Chief Financial Officer. Today's discussion includes forward-looking statements based on our current expectations and management's judgment as of today. Actual results could differ materially because of risks and uncertainties, including those described in our SEC filings. Please refer to these filings, which are available through the SEC and on our website, for information concerning risk factors that could affect the company. With that, I'll turn the call over to Troy.
Thank you, Greg. Good afternoon, everyone. I'm happy to report we delivered another quarter of strong growth and sustained commercial leadership. KOMZIFTI net product revenue reached $13.9 million, up 53% sequentially, while new patient starts increased 30%. We maintained a majority share of menin inhibitor new patient starts, reflecting continued physician preference for KOMZIFTI. Our priority is to grow our leadership in this setting while building the clinical evidence to support expansion into earlier treatment settings and combinations. We're heading into ASH with an unprecedented ziftomenib presence, including four oral presentations and our first clinical data on ziftomenib combined with FLT3 inhibitors in both newly diagnosed and relapsed and refractory AML. Roughly half of patients with NPM1-mutated AML have a concurrent FLT3 mutation, and that prevalence makes FLT3 inhibitor combinations a critical part of our strategy to establish ziftomenib as a foundational AML therapy.
These studies are among eight ziftomenib abstracts at ASH, and Molly will discuss how these studies address the opportunity and inform our next development decisions. Turning to our FTI program, we are very excited to announce we have aligned with FDA on a single-arm monotherapy registrational study with darlifarnib in HRAS-mutant salivary gland cancer. This puts our second potential precision oncology product on a focused path toward registration. Although this approach may deliver a new class of treatment in a molecularly defined patient population with substantial unmet need, importantly, it could also provide a strong clinical, regulatory, and commercial foundation while we pursue larger indications in combination and through supplemental applications. We enter this next phase for Kura from a position of financial strength. Our strategic financing agreement with Oberland Capital gives us flexibility to deliver key milestones for ziftomenib and darlifarnib.
I am pleased to welcome Jennifer to her first call as our Chief Financial Officer. She will discuss the financing, our funding outlook, and our capital allocation priorities. Finally, we established Caspian Therapeutics to advance menin inhibitors for diabetes and other chronic metabolic diseases. Kura contributed KO-7246 and related intellectual property and know-how. Caspian's dedicated leadership and financing allow Kura to maintain our operating focus on oncology while retaining a substantial ownership interest in the program's potential value. With that, I will turn the call over to Brian to discuss our commercial performance.
Brian? Thank you, Troy. KOMZIFTI's third quarter performance reinforces our leadership in the menin inhibitor market in relapsed or refractory NPM1-mutant AML.
Physician feedback continues to align with our four pillars of differentiation: efficacy, a predictable and manageable safety profile, combinability and compatibility with other medicines, and convenient once-daily oral dosing. Together, these attributes are translating into broader adoption and sustained growth. The trend is clear. We grew revenue, added prescribing accounts, and increased repeat prescriptions. Our focus is to continue to convert that leadership and momentum into sustained growth. In Q3, KOMZIFTI net product revenue was up 53% over Q2. We recorded approximately 150 new patient starts, up approximately 30%, and more than 420 total prescriptions, up 65%. We maintained a majority share of menin inhibitor new patient starts in relapsed or refractory NPM1-mutated AML. These results demonstrate our team's strong execution in a competitive market.
New patient starts measure adoption and drive future prescription demand. Total prescriptions grew faster than new starts, which indicates a larger contribution from refills as our treated patient base expands. Our Kura and Kyowa Kirin field teams continue to expand our reach with AML prescribers and care teams. A total of 170 accounts have now prescribed KOMZIFTI, up 40% quarter-over-quarter. Prescribing also increased in high and medium priority accounts. During the quarter, our combined field teams reached 97% of our highest priority AML accounts, working with physicians, pharmacists, and care teams to identify appropriate patients and support treatment initiation and refills. Access remains a clear strength. KOMZIFTI has coverage for nearly 100% of covered lives, with favorable formulary positioning in multiple plans. Our patient support program helps patients navigate access and affordability, start treatment promptly, and stay on therapy as prescribed.
In the available claims dataset, nearly half of KOMZIFTI patients received it in combination with other approved agents, primarily venetoclax and azacitidine or FLT3 inhibitors. While our teams promote KOMZIFTI only for its approved indication, these real-world observational data reflect how physicians are using combination strategies in clinical practice with the goal of improving patient outcomes. We are thrilled with our team's performance, and we intend to build on these strong results. For the remainder of this year, our priorities are to sustain growth in the approved population, expand the number of prescribing accounts, support timely treatment initiation and refills, and increase repeat prescribing within existing accounts. We will continue to report new patient starts, total prescriptions, and net product revenue so you can track our progress. We continue to strengthen KOMZIFTI's position in the approved setting.
The prescribing experience and physician relationships we build today will support future expansion, where the benefits of combinability with other standards of care without overlapping toxicity will be the differentiator among menin inhibitors. Early results support our thesis, and we believe our development strategy will establish ziftomenib as a foundational therapy across AML. With that, I will turn the call over to Mollie for a discussion on the development updates.
Mollie? Thank you, Brian. Our clinical strategy is to establish ziftomenib as a backbone therapy across the menin-dependent AML treatment continuum and build a second precision oncology franchise with darlifarnib.
Our near-term focus is the upcoming ASH data, execution of KOMET-017 frontline program, and advancement of darlifarnib's registrational and combination studies. At ASH, we are very pleased to have eight ziftomenib abstracts, including four oral presentations. Among those, we want to draw your attention to our first clinical trial data evaluating ziftomenib in combination with two different FLT3 inhibitors during two oral presentations. Data will come from the ongoing ziftomenib trials, KOMET-007 and 008. The prevalence of FLT3 mutations in AML makes it a priority to generate this combination data. Nearly one-third of patients with AML and nearly half of all patients with NPM1 mutations have a FLT3 mutation.
From the frontline KOMET-007 study, we will be presenting data from the quad combination of ziftomenib plus quizartinib with intensive chemotherapy that shows encouraging results in newly diagnosed NPM1-mutated FLT3-ITD-positive AML patients, clearly supporting further investigation. KOMET-008 is evaluating ziftomenib plus gilteritinib in relapsed or refractory NPM1 mutant FLT3 co-mutated AML. These data will show encouraging activity and tolerability, including in patients previously treated with a FLT3 inhibitor. Two additional poster presentations will add to the evidence supporting ziftomenib in combination with current standards of care. The first is an update with longer-term follow-up on the combination of ziftomenib plus ven/aza in the frontline setting from KOMET-007. These data support our continued excitement around the NIC portion of our phase III KOMET-017 trial.
The second poster will provide additional data from our KOMET-001 trial, with an exploratory analysis of ziftomenib's activity in molecularly defined AML subtypes beyond NPM1-mutated and KMT2A-rearranged disease, such as DNMT3A mutation-driven disease, informing potential opportunities to reach more patients. Together, these presentations will broaden the clinical evidence for ziftomenib across molecular subtypes, treatment settings, and combination regimens. ASH will also feature an oral presentation where we present encouraging first results from Blood Cancer United and Princess Máxima Center's PedAL trial of ziftomenib plus fludarabine and cytarabine in heavily pretreated pediatric patients with relapsed or refractory acute leukemia, including those previously treated with revumenib. Another oral presentation will highlight preclinical findings in additional subsets of menin-associated leukemias. From the beginning, our strategy has been to get combinations and frontline treatments to patients. We are there today. We are presenting combinations of FLT3 and standard of care chemo at ASH next month.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
16 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
